ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Spyre Therapeutics Inc

Spyre Therapeutics Inc (SYRE)

22,35
0,20
( 0,90% )
Aktualisiert: 15:45:03

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Current Price
22,35
Gebot
22,06
Fragen
22,38
Volumen
13.262
21,13 Tagesbereich 22,44
20,07 52-Wochen-Bereich 47,97
Marktkapitalisierung
Handelsende
22,15
Handelsbeginn
21,63
Letzte Trade
25
@
22.22
Letzter Handelszeitpunkt
15:46:46
Finanzvolumen
US$ 288.414
VWAP
21,7474
Durchschnittliches Volumen (3 Mio.)
576.205
Ausgegebene Aktien
51.431.220
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-3,30
Gewinn pro Aktie (EPS)
-6,59
Erlöse
886k
Nettogewinn
-338,79M

Über Spyre Therapeutics Inc

Spyre Therapeutics, Inc. is a biotechnology company. The Company is engaged in creating inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches. Its pipeline includes investigational extended half-life antibodie... Spyre Therapeutics, Inc. is a biotechnology company. The Company is engaged in creating inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches. Its pipeline includes investigational extended half-life antibodies targeting a4B7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, and SPY230. It has nominated development candidates for SPY001 and SPY002. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4B7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a discovery-stage program focused on designing antibodies to bind to Interleukin 23 (IL-23). Mehr anzeigen

Sektor
Pharmaceutical Preparations
Branche
Pharmaceutical Preparations
Website
Hauptsitz
Wilmington, Delaware, USA
Gegründet
-
Spyre Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker SYRE. The last closing price for Spyre Therapeutics was US$22,15. Over the last year, Spyre Therapeutics shares have traded in a share price range of US$ 20,07 to US$ 47,97.

Spyre Therapeutics currently has 51.431.220 shares in issue. The market capitalisation of Spyre Therapeutics is US$1,14 billion. Spyre Therapeutics has a price to earnings ratio (PE ratio) of -3.30.

SYRE Neueste Nachrichten

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1-1.43-6.0134566862923.7824.8321.1364992022.81041736CS
40.462.1014161717721.8924.8320.2561897322.19447717CS
12-4.535-16.868142086726.88529.0920.2557620524.12490068CS
26-2.53-10.168810289424.8840.120.2554408327.33805811CS
52-1.32-5.5766793409423.6747.9720.0755473529.08038823CS
15611.54106.75300647510.8147.9710.4250100428.56081911CS
26011.54106.75300647510.8147.9710.4250100428.56081911CS

SYRE - Frequently Asked Questions (FAQ)

What is the current Spyre Therapeutics share price?
The current share price of Spyre Therapeutics is US$ 22,35
How many Spyre Therapeutics shares are in issue?
Spyre Therapeutics has 51.431.220 shares in issue
What is the market cap of Spyre Therapeutics?
The market capitalisation of Spyre Therapeutics is USD 1,14B
What is the 1 year trading range for Spyre Therapeutics share price?
Spyre Therapeutics has traded in the range of US$ 20,07 to US$ 47,97 during the past year
What is the PE ratio of Spyre Therapeutics?
The price to earnings ratio of Spyre Therapeutics is -3,3
What is the cash to sales ratio of Spyre Therapeutics?
The cash to sales ratio of Spyre Therapeutics is 1,27k
What is the reporting currency for Spyre Therapeutics?
Spyre Therapeutics reports financial results in USD
What is the latest annual turnover for Spyre Therapeutics?
The latest annual turnover of Spyre Therapeutics is USD 886k
What is the latest annual profit for Spyre Therapeutics?
The latest annual profit of Spyre Therapeutics is USD -338,79M
What is the registered address of Spyre Therapeutics?
The registered address for Spyre Therapeutics is 1521 CONCORD PIKE, SUITE 201, NEW CASTLE, WILMINGTON, DELAWARE, 19803
What is the Spyre Therapeutics website address?
The website address for Spyre Therapeutics is www.spyre.com
Which industry sector does Spyre Therapeutics operate in?
Spyre Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
GSATGlobalstar Inc
US$ 23,1621
(5.690,53%)
112,26k
XLOXilio Therapeutics Inc
US$ 1,4001
(113,11%)
61,79M
NXUNXU Inc
US$ 0,4731
(72,73%)
119,19M
TIVCTivic Health Systems Inc
US$ 0,3902
(66,04%)
78,78M
AIFFFirefly Neuroscience Inc
US$ 12,8849
(53,39%)
28,84M
ALCEAlternus Clean Energy Inc
US$ 0,0801
(-64,56%)
756,08k
ATOMAtomera Incorporated
US$ 4,8895
(-43,47%)
1,51M
STAASTAAR Surgical Company
US$ 14,965
(-31,60%)
1,55M
KALAKALA BIO Inc
US$ 8,02
(-26,29%)
144,75k
OSOneStream Inc
US$ 22,46
(-25,58%)
1,35M
NXUNXU Inc
US$ 0,4731
(72,73%)
121,42M
WINTWindtree Therapeutics Inc
US$ 0,1905
(19,06%)
93,4M
TIVCTivic Health Systems Inc
US$ 0,3902
(66,04%)
85,48M
APTOAptose Biosciences Inc
US$ 0,2135
(18,55%)
72,9M
XLOXilio Therapeutics Inc
US$ 1,4001
(113,11%)
63,72M
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

Delayed Upgrade Clock